Adherence and impact of an oral nutritional supplement enriched in leucine, EVOO, EPA and DHA, and beta-glucans on the coverage of energy and protein requirements in patients with cancer and malnutrition: Alisenoc study.

Plain-language guide to PMID 38341907 (2024): double-blind randomized controlled trial of Copper (Supplement).

Key Facts

PMID: 38341907
Journal: Nutrition (Burbank, Los Angeles County, Calif.)
Year: 2024
Study type: Randomized Controlled Trial
Authors: Milla SP et al. (11 authors)
DOI: 10.1016/j.nut.2024.112355

What This Study Did, in Plain Language

What Was Tested

Researchers studied Copper (Supplement) in this randomized controlled trial publication.

The aim of this study was to evaluate the impact of an enhanced ONS (enriched in EPA, DHA, leucine, and beta-glucans) on the dietary intake of cancer patients.

Who Took Part

A randomized, double-blind, parallel, controlled, and multicenter clinical trial was conducted in patients with cancer and malnutrition.

Food intake was assessed with a 3-day dietary survey, and adherence to the supplement with a patient self-completed diary.

How the Study Was Run

The design is described as randomized, double-blind, multicenter and parallel-group.

Because people in this Copper (Supplement) study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Blinding on both sides kept the participants and researchers unaware of who received Copper (Supplement).

Running at several centres spread the Copper (Supplement) study over different clinics and patient groups.

The Copper (Supplement) group and the comparison group ran side by side rather than switching.

What Was Measured

PubMed files the paper under topics including beta-Glucans, Dietary Supplements, Leucine, Malnutrition, Neoplasms, Nutritional Status and Medication Adherence.

The authors tagged it with the keywords Cancer, dietary counseling, disease-related malnutrition, omega-3 and oral nutritional supplement.

What This Means in Plain Language

The paper is a randomized, double-blind and multicenter study of Copper (Supplement).

Its findings take up roughly 5 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2024 (Nutrition (Burbank, Los Angeles County, Calif.)), a journal based in United States.

More context: the Copper (Supplement) compound page, all human trials.

Our Notes on the Compound

Copper (Supplement): The active site of cytochrome c oxidase is described as containing copper ions that are essential for electron transfer.

Copper (Supplement) in the library

Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.